HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G buys HDS Cosmetics Lab

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble gains firm's Doctor's Dermatologic Formula (DDF) skin care line - designed for specific skin concerns such as anti-aging, acne, hyperpigmentation and sun protection - through an acquisition announced Jan. 22. Lauding DDF as a "leading dermatologist brand in the retail specialty channel [with] a strong following of loyal consumers," P&G says it will "infuse the line with a steady stream of innovation, add marketing expertise and leverage its global reach and go-to-market capability to drive future expansion." The move reflects P&G's sharpening focus on skin care as a key growth driver, company adds. P&G acquired the company from private equity firm North Castle Partners, which purchased a controlling interest in HDS in 2004 (1"The Rose Sheet" April 12, 2004, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel